Humacyte.

PositionDURHAM

Humacyte received a $1 50 million investment from Boston-based Fresenius Medical Care. Fresenius will gain exclusive rights to commercialize Humacyl, a blood vessel product made with...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT